Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab

Cancer Research

Volumn 67, Issue 8, 2007, Pages 3518-3523

  Binder, Mascha ^a   Vögtle, Friederike Nora ^a   Michelfelder, Stefan ^a   Müller, Fabian ^a   Illerhaus, Gerald ^a   Sundararajan, Sangeeth ^a   Mertelsmann, Roland ^a   Trepel, Martin ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BASILIXIMAB; DACLIZUMAB; EPITOPE; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ARTICLE; BACTERIOPHAGE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; TISSUE TRANSPLANTATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BINDING SITES; CELL LINE; EPITOPES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN CONFORMATION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS;

EID: 34248569824     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3919     Document Type: Article

References (22)

1. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997;350: 1193-8.
2. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994;84:1320-7.
3. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor a chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95:83-9.
4. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993;82:1701-12.
5. Pankhurst T, Adu D. Antibodies in the prevention of renal allograft rejection. Expert Opin Biol Ther 2004;4: 243-52.
6. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors. Science 2005;310:1159-63.
7. Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its a receptor. Science 2005;308:1477-80.
8. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. J Immunol 1981;126:1398-403.
9. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004;56:864-7.
10. Leonard WJ, Depper JM, Robb RJ, Waldmann TA, Greene WC. Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci U S A 1983;80: 6957-61.
11. Soulillou JP. Immunosuppression through inhibition of interleukin-2/interleukin-2 receptor interaction. Transplant Proc 1999;31:49-51S.
12. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990;249:386-90.
13. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006;108: 1975-8.
14. Riemer AB, Klinger M, Wagner S, et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004;173:394-401.
15. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003;21:57-63.
16. Vidal CI, Mintz PJ, Lu K, et al. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene 2004;23: 8859-67.
17. Muller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003;21:1040-6.
18. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006;107:1070-7.
19. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005;97:1663-70.
20. Fellouse FA, Li B, Compaan DM, Peden AA, Hymowitz SG, Sidhu SS. Molecular recognition by a binary code. J Mol Biol 2005;348:1153-62.
21. Villar HO, Kauvar LM. Amino acid preferences at protein binding sites. FEBS Lett 1994;349:125-30.
22. Fellouse FA, Barthelemy PA, Kelley RF, Sidhu SS. Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. J Mol Biol 2006;357:100-14.